selected scholarly activity
-
conferences
- Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). Cancer Research. 2022
- The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement.. Journal of Clinical Oncology. e23142-e23142. 2019
- Assessment of myocardial injury early after initiation of treatment in breast cancer patients using the Beckman Coulter and Abbott Diagnostics high-sensitivity cardiac troponin I tests. Clinical Biochemistry. 56-57. 2018
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects). International Journal of Radiation Oncology Biology Physics. S88-S89. 2018
- Adenomyoepithelioma with carcinoma of the breast: case report with next generation sequencing. Virchows Archiv. S52-S52. 2018
- Evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.. Journal of Clinical Oncology. e18548-e18548. 2018
- Abstract P5-20-17: Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study. Cancer Research. p5-20-17-p5-20-17. 2018
- Safety of continuing chemotherapy in overt left ventricular dysfunction using antibodies to human epidermal growth factor receptor-2: A retrospective study. Cancer Research. 2018
- Code status communication training in Canadian postgraduate oncology programs: A needs assessment survey.. Journal of Clinical Oncology. 13-13. 2017
- The PULSES project: Teaching the vital elements of code status discussions to oncology residents.. Journal of Clinical Oncology. 46-46. 2017
- Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC). Cancer Research. CT131-CT131. 2017
- Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre.. Journal of Clinical Oncology. e12030-e12030. 2017
- The PULSES project: Teaching the vital elements of code status discussions to oncology residents.. Journal of Clinical Oncology. 10024-10024. 2017
- Abstract 3787: Thyroid hormone induced proliferation of breast cancer cell lines: A novel approach to hormone therapy. Cancer Research. 3787-3787. 2016
- Expression of the CD200 tolerance signaling molecule and its receptor (CD200R1) in normal and malignant trophoblasts. Journal of Reproductive Immunology. 30-31. 2015
- Abstract 1154: Serum and urine markers of metabolic dysfunction in colorectal cancer: A pilot study. Cancer Research. 1154-1154. 2015
- Blood and urine markers of metabolic dysfunction in colorectal cancer: a pilot study.. Journal of Clinical Oncology. e14611-e14611. 2015
- Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC). Journal of Clinical Oncology. 2015
- Assessment of galectin-3, N-terminal pro-brain natriuretic peptide and inflammatory cytokines in patients with myocardial injury after initiation of adjuvant trastuzumab therapy. Clinical Biochemistry. 1144-1144. 2014
- Prognostic potential of thyroid receptor TRα2 in breast cancer.. Journal of Clinical Oncology. e11535-e11535. 2014
- Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients.. Journal of Clinical Oncology. 2013
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 2012
- Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC).. Journal of Clinical Oncology. 2012
- Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC). Modern Pathology. 36A-36A. 2012
- Chromosome 17 Polysomy and Monosomy as Predictive Markers of Complete Pathological Response (pCR) in Women with Locally Advanced Breast Cancer (LABC). Laboratory Investigation. 36A-36A. 2012
- NT-proBNP measurement using a multiplex platform in cancer and chest pain populations. Clinical Biochemistry. 1172-1172. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 2011
- HER2/neu Testing in Breast Carcinoma. Concordance Study Fluorescent In Situ Hybridization (FISH) vs. Chromogenic In Situ Hybridization (CISH). Modern Pathology. 38A-38A. 2009
- HER2/neu Testing in Breast Carcinoma. Concordance Study Fluorescent In Situ Hybridization (FISH) vs. Chromogenic In Situ Hybridization (CISH). Laboratory Investigation. 38A-38A. 2009
- Value of Chemotherapy with ECF in Advanced Esophageal Cancer Treated with Endoscopic Guided High Dose Rate Intraluminal Brachytherapy (EGHDRILBT). International Journal of Radiation Oncology Biology Physics. S267-S267. 2008
- Generalizability of results from oncology clinical trials: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 6633-6633. 2008
- Patterns of adjuvant systemic therapy in elderly with breast cancer (BC). Journal of Clinical Oncology. 11597-11597. 2008
- Tertiary center breast cancer pathology review: Positive impact on patient care. Laboratory Investigation. 30A-30A. 2007
- Phase II pilot study on brachytherapy with ECF vs brachytherapy and standard chemoradiation in esophageal cancer. Annals of Oncology. VII90-VII91. 2007
- 2177. International Journal of Radiation Oncology Biology Physics. S308-S308. 2006
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases. Journal of Clinical Oncology. 3198-3198. 2005
-
internet publications
-
journal articles
- Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab. Oncologist. 28:e712-e722. 2023
- Detection of Macrotroponin in Patients Receiving Treatment for Breast Cancer. CJC Open. 5:658-660. 2023
- Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial (SWOG S1007). Cancer Research. 83. 2023
- Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC). Cancer Research. 83. 2023
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of Clinical Oncology. 40:787-800. 2022
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine. 385:2336-2347. 2021
- Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. CJC Open. 3:1372-1382. 2021
- Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. iScience. 24:102619-102619. 2021
- Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. Journal of Bone Oncology. 26:100343-100343. 2021
- Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment.. Current Oncology. 27:607-613. 2020
- Breaking silence: a survey of barriers to goals of care discussions from the perspective of oncology practitioners. BMC Cancer. 19:130. 2019
- Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?. Oncologist. 24:1405-1409. 2019
- Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists. Breast Journal. 25:1222-1224. 2019
- Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity. JACC: CardioOncology. 1:1-10. 2019
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta. 495:355-357. 2019
- An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction. Current Oncology. 26:240-246. 2019
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. Clinical Oncology. 31:479-485. 2019
- Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab. Canadian Journal of Cardiology. 35:545.e1-545.e2. 2019
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. Breast Cancer Research and Treatment. 171:709-717. 2018
- Soluble CD200 in secretory phase endometriosis endometrial venules may explain endometriosis pathophysiology and provide a novel treatment target. Journal of Reproductive Immunology. 129:59-67. 2018
- Human Papillomavirus Status and Esophageal Adenocarcinoma. JAMA network open. 1:e181415-e181415. 2018
- Clinical Practice Guidelines in Breast Cancer. Current Oncology. 25:151-160. 2018
- Role of allied health care professionals in goals-of-care discussions with hospitalized patients and perceived barriers: a cross-sectional survey. CMAJ open. 6:E241-E247. 2018
- A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment. 167:485-493. 2018
- Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 13:e0209486-e0209486. 2018
- Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology. 35:3978-3986. 2017
- Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours. Breast Cancer Research. 19:76. 2017
- Reply to T.J. Powles et al. Journal of Clinical Oncology. 35:2720-2721. 2017
-
Changes in expression of the
CD 200 tolerance‐signaling molecule and its receptor (CD 200R) by villus trophoblasts during first trimester missed abortion and in chronic histiocytic intervillositis. Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy. 78. 2017 - Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 35:2062-2081. 2017
- Uptake of a 21-Gene Expression Assay in Breast Cancer Practice: Views of Academic and Community-Based Oncologists. Current Oncology. 24:138-145. 2017
- Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. Journal of Gastrointestinal Oncology. 8:32-38. 2017
- Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine. Hypoxic Signaling. Volume 5:61-66. 2017
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology. 34:3914-3920. 2016
- Corrigendum to “The CD200 tolerance-signaling molecule and its receptor, CD200R1, are expressed in human placental villus trophoblast and in peri-implant decidua by 5 weeks’ gestation” [J. Reprod. Immunol. 112 (2015) 20–23]. Journal of Reproductive Immunology. 117:89-90. 2016
- Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment. 157:109-116. 2016
- The CD200 tolerance-signaling molecule and its receptor, CD200R1, are expressed in human placental villus trophoblast and in peri-implant decidua by 5 weeks’ gestation. Journal of Reproductive Immunology. 112:20-23. 2015
-
The Receptor for the
CD 200 Tolerance‐Signaling Molecule Associated with Successful Pregnancy is Expressed by Early‐Stage Breast Cancer Cells in 80% of Patients and by Term Placental Trophoblasts. Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy. 74:387-391. 2015 - Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC).. Journal of Clinical Oncology. 33:e12082-e12082. 2015
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. British Journal of Cancer. 112:1737-1743. 2015
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Research and Treatment. 149:293-301. 2015
- Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. Clinical Biochemistry. 47:155-157. 2014
- The CD200-tolerance Signaling Molecule Associated with Pregnancy Success is Present In Patients with Early-stage Breast Cancer but Does not Favor Nodal Metastasis. Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy. 72:435-439. 2014
- PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).. Journal of Clinical Oncology. 32:4022-4022. 2014
- Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy. Clinical Chemistry. 59:327-329. 2013
- Cancer Care Ontario Guideline Recommendations for Hormone Receptor Testing in Breast Cancer. Clinical Oncology. 24:684-696. 2012
- Is Colon Cancer Survival Influenced by Tumor Location?. Journal of Clinical Oncology. 30:1732-1733. 2012
- Screening for Osteoporosis in Postmenopausal Women With Breast Cancer Receiving Aromatase Inhibitors: Less Is More?. Journal of Clinical Oncology. 30:1408-1410. 2012
- Systematic Review on Hormone Receptor Testing in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology. 20:214-263. 2012
- Chemotherapy for colorectal cancer. The Lancet Oncology. 13:e3-e4. 2012
- Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC). Clinical Biochemistry. 44:1273-1277. 2011
- Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population. Journal of Clinical Oncology. 29:e177-e177. 2011
- Generalizability of Toxicity Data from Oncology Clinical Trials to Clinical Practice: Toxicity of Irinotecan-Based Regimens in Patients with Metastatic Colorectal Cancer. Current Oncology. 16:13-20. 2009
- Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CANADIAN MEDICAL ASSOCIATION JOURNAL. 172:1319-1320. 2005
- Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines. Current Oncology. 9:7-12. 2002